Abbott Receives FDA Clearance For AI-powered Heart Imaging Software

Abbott has received clearance from the FDA for its imaging software that uses artificial intelligence to provide doctors a better view of blood flow and blockages in heart vessels.

Abbott landed FDA clearance for its imaging software, which employs artificial intelligence to give doctors a clearer look at blood flow and blockages in heart vessels.

The Ultreon 1.0 Software pairs optical coherence tomography with AI to help physicians make decisions about next steps for treatment.

"As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care," Dr. Nick West, chief medical officer and divisional vice president of global medical affairs at Abbott's vascular business, said in a statement.

"AI enables Ultreon Software to automatically detect calcium and vessel diameters, allowing doctors to put stents exactly where they are needed."

This is Abbott’s second FDA clearance this week. The company’s FreeStyle Libre 2 got the greenlight to allow users with diabetes to access their glucose levels on their iPhones without a reader.